nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—L-DOPA—Melphalan—breast cancer	0.222	1	CrCrCtD
Mesalazine—PTGS1—breast cancer	0.191	0.636	CbGaD
Mesalazine—PTGS2—breast cancer	0.109	0.364	CbGaD
Mesalazine—MPO—Carboplatin—breast cancer	0.0401	1	CbGbCtD
Mesalazine—PPARG—Topotecan—Irinotecan—breast cancer	0.00211	1	CbGdCrCtD
Mesalazine—IKBKB—nipple—breast cancer	0.00192	0.0365	CbGeAlD
Mesalazine—CHUK—epithelium—breast cancer	0.00191	0.0362	CbGeAlD
Mesalazine—CHUK—skin of body—breast cancer	0.00181	0.0344	CbGeAlD
Mesalazine—IKBKB—embryo—breast cancer	0.00159	0.0301	CbGeAlD
Mesalazine—CHUK—adipose tissue—breast cancer	0.00154	0.0292	CbGeAlD
Mesalazine—PPARG—mammary gland—breast cancer	0.00145	0.0275	CbGeAlD
Mesalazine—CHUK—female reproductive system—breast cancer	0.00142	0.0269	CbGeAlD
Mesalazine—CHUK—adrenal gland—breast cancer	0.00138	0.0262	CbGeAlD
Mesalazine—CHUK—female gonad—breast cancer	0.00129	0.0244	CbGeAlD
Mesalazine—IKBKB—skin of body—breast cancer	0.00123	0.0234	CbGeAlD
Mesalazine—CHUK—endocrine gland—breast cancer	0.0012	0.0227	CbGeAlD
Mesalazine—PPARG—nipple—breast cancer	0.0012	0.0227	CbGeAlD
Mesalazine—IKBKB—endometrium—breast cancer	0.00116	0.022	CbGeAlD
Mesalazine—IKBKB—uterus—breast cancer	0.00107	0.0203	CbGeAlD
Mesalazine—IKBKB—pituitary gland—breast cancer	0.00105	0.0199	CbGeAlD
Mesalazine—IKBKB—adipose tissue—breast cancer	0.00105	0.0199	CbGeAlD
Mesalazine—PPARG—embryo—breast cancer	0.000988	0.0187	CbGeAlD
Mesalazine—IKBKB—female reproductive system—breast cancer	0.000962	0.0183	CbGeAlD
Mesalazine—IKBKB—adrenal gland—breast cancer	0.000939	0.0178	CbGeAlD
Mesalazine—MPO—epithelium—breast cancer	0.000908	0.0172	CbGeAlD
Mesalazine—IKBKB—female gonad—breast cancer	0.000875	0.0166	CbGeAlD
Mesalazine—ALOX5—adipose tissue—breast cancer	0.000867	0.0165	CbGeAlD
Mesalazine—MPO—skin of body—breast cancer	0.000864	0.0164	CbGeAlD
Mesalazine—CHUK—lymph node—breast cancer	0.000828	0.0157	CbGeAlD
Mesalazine—IKBKB—endocrine gland—breast cancer	0.000814	0.0155	CbGeAlD
Mesalazine—PPARG—epithelium—breast cancer	0.000806	0.0153	CbGeAlD
Mesalazine—ALOX5—female reproductive system—breast cancer	0.000797	0.0151	CbGeAlD
Mesalazine—ALOX5—adrenal gland—breast cancer	0.000778	0.0148	CbGeAlD
Mesalazine—PPARG—skin of body—breast cancer	0.000767	0.0145	CbGeAlD
Mesalazine—ALOX5—bone marrow—breast cancer	0.000753	0.0143	CbGeAlD
Mesalazine—MPO—pituitary gland—breast cancer	0.000737	0.014	CbGeAlD
Mesalazine—Olsalazine—IFNG—breast cancer	0.000726	0.195	CrCbGaD
Mesalazine—ALOX5—female gonad—breast cancer	0.000726	0.0138	CbGeAlD
Mesalazine—ALOX5—endocrine gland—breast cancer	0.000675	0.0128	CbGeAlD
Mesalazine—PPARG—uterus—breast cancer	0.000666	0.0126	CbGeAlD
Mesalazine—MPO—adrenal gland—breast cancer	0.000658	0.0125	CbGeAlD
Mesalazine—PPARG—adipose tissue—breast cancer	0.000651	0.0124	CbGeAlD
Mesalazine—PTGS1—nipple—breast cancer	0.00064	0.0121	CbGeAlD
Mesalazine—MPO—bone marrow—breast cancer	0.000637	0.0121	CbGeAlD
Mesalazine—PPARG—female reproductive system—breast cancer	0.000599	0.0114	CbGeAlD
Mesalazine—PPARG—adrenal gland—breast cancer	0.000584	0.0111	CbGeAlD
Mesalazine—MPO—endocrine gland—breast cancer	0.000571	0.0108	CbGeAlD
Mesalazine—PPARG—bone marrow—breast cancer	0.000565	0.0107	CbGeAlD
Mesalazine—IKBKB—lymph node—breast cancer	0.000563	0.0107	CbGeAlD
Mesalazine—PPARG—female gonad—breast cancer	0.000545	0.0103	CbGeAlD
Mesalazine—PPARG—endocrine gland—breast cancer	0.000507	0.00962	CbGeAlD
Mesalazine—PTGS2—embryo—breast cancer	0.000505	0.00958	CbGeAlD
Mesalazine—ALOX5—lymph node—breast cancer	0.000466	0.00885	CbGeAlD
Mesalazine—Methyldopa—COMT—breast cancer	0.000449	0.12	CrCbGaD
Mesalazine—PTGS1—epithelium—breast cancer	0.000431	0.00818	CbGeAlD
Mesalazine—PTGS2—epithelium—breast cancer	0.000412	0.00782	CbGeAlD
Mesalazine—PTGS1—skin of body—breast cancer	0.00041	0.00778	CbGeAlD
Mesalazine—MPO—lymph node—breast cancer	0.000395	0.00749	CbGeAlD
Mesalazine—PTGS2—skin of body—breast cancer	0.000392	0.00743	CbGeAlD
Mesalazine—PTGS1—endometrium—breast cancer	0.000386	0.00733	CbGeAlD
Mesalazine—PTGS2—endometrium—breast cancer	0.000369	0.00701	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS1—breast cancer	0.000369	0.0988	CrCbGaD
Mesalazine—PTGS1—uterus—breast cancer	0.000356	0.00676	CbGeAlD
Mesalazine—PPARG—lymph node—breast cancer	0.00035	0.00665	CbGeAlD
Mesalazine—PTGS1—pituitary gland—breast cancer	0.00035	0.00664	CbGeAlD
Mesalazine—PTGS1—adipose tissue—breast cancer	0.000348	0.00661	CbGeAlD
Mesalazine—PTGS2—uterus—breast cancer	0.00034	0.00646	CbGeAlD
Mesalazine—PTGS2—pituitary gland—breast cancer	0.000334	0.00634	CbGeAlD
Mesalazine—PTGS2—adipose tissue—breast cancer	0.000333	0.00632	CbGeAlD
Mesalazine—PTGS1—female reproductive system—breast cancer	0.00032	0.00607	CbGeAlD
Mesalazine—PTGS1—adrenal gland—breast cancer	0.000312	0.00593	CbGeAlD
Mesalazine—PTGS2—female reproductive system—breast cancer	0.000306	0.00581	CbGeAlD
Mesalazine—PTGS2—adrenal gland—breast cancer	0.000299	0.00567	CbGeAlD
Mesalazine—PTGS1—female gonad—breast cancer	0.000291	0.00553	CbGeAlD
Mesalazine—PTGS2—bone marrow—breast cancer	0.000289	0.00548	CbGeAlD
Mesalazine—PTGS2—female gonad—breast cancer	0.000278	0.00528	CbGeAlD
Mesalazine—PTGS1—endocrine gland—breast cancer	0.000271	0.00514	CbGeAlD
Mesalazine—PTGS2—endocrine gland—breast cancer	0.000259	0.00491	CbGeAlD
Mesalazine—Olsalazine—PTGS1—breast cancer	0.000253	0.0677	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS1—breast cancer	0.000238	0.0636	CrCbGaD
Mesalazine—Diflunisal—PTGS1—breast cancer	0.000238	0.0636	CrCbGaD
Mesalazine—Dopamine—COMT—breast cancer	0.000219	0.0587	CrCbGaD
Mesalazine—Salicylate-sodium—PTGS2—breast cancer	0.000211	0.0565	CrCbGaD
Mesalazine—PTGS1—lymph node—breast cancer	0.000187	0.00355	CbGeAlD
Mesalazine—PTGS2—lymph node—breast cancer	0.000179	0.0034	CbGeAlD
Mesalazine—Olsalazine—PTGS2—breast cancer	0.000144	0.0387	CrCbGaD
Mesalazine—Diflunisal—PTGS2—breast cancer	0.000136	0.0364	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—breast cancer	0.000136	0.0364	CrCbGaD
Mesalazine—Salicylic acid—PTGS1—breast cancer	0.000132	0.0354	CrCbGaD
Mesalazine—Diflunisal—ALB—breast cancer	0.000121	0.0324	CrCbGaD
Mesalazine—L-DOPA—CYP2D6—breast cancer	8.05e-05	0.0216	CrCbGaD
Mesalazine—Salicylic acid—PTGS2—breast cancer	7.56e-05	0.0202	CrCbGaD
Mesalazine—Dopamine—CYP2D6—breast cancer	7.49e-05	0.0201	CrCbGaD
Mesalazine—Salicylic acid—ALB—breast cancer	6.73e-05	0.018	CrCbGaD
Mesalazine—Salicylic acid—ABCB1—breast cancer	6.42e-05	0.0172	CrCbGaD
Mesalazine—Decreased appetite—Docetaxel—breast cancer	2.04e-05	9.47e-05	CcSEcCtD
Mesalazine—Hypersensitivity—Paclitaxel—breast cancer	2.04e-05	9.47e-05	CcSEcCtD
Mesalazine—Headache—Fluorouracil—breast cancer	2.04e-05	9.46e-05	CcSEcCtD
Mesalazine—Urinary tract disorder—Doxorubicin—breast cancer	2.04e-05	9.45e-05	CcSEcCtD
Mesalazine—Oedema peripheral—Doxorubicin—breast cancer	2.03e-05	9.43e-05	CcSEcCtD
Mesalazine—Dysgeusia—Methotrexate—breast cancer	2.03e-05	9.42e-05	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Docetaxel—breast cancer	2.03e-05	9.41e-05	CcSEcCtD
Mesalazine—Connective tissue disorder—Doxorubicin—breast cancer	2.03e-05	9.41e-05	CcSEcCtD
Mesalazine—Dyspnoea—Capecitabine—breast cancer	2.03e-05	9.4e-05	CcSEcCtD
Mesalazine—Fatigue—Docetaxel—breast cancer	2.02e-05	9.39e-05	CcSEcCtD
Mesalazine—Angiopathy—Epirubicin—breast cancer	2.02e-05	9.39e-05	CcSEcCtD
Mesalazine—Urethral disorder—Doxorubicin—breast cancer	2.02e-05	9.38e-05	CcSEcCtD
Mesalazine—Nausea—Mitoxantrone—breast cancer	2.02e-05	9.36e-05	CcSEcCtD
Mesalazine—Nausea—Irinotecan—breast cancer	2.02e-05	9.36e-05	CcSEcCtD
Mesalazine—Immune system disorder—Epirubicin—breast cancer	2.01e-05	9.34e-05	CcSEcCtD
Mesalazine—Mediastinal disorder—Epirubicin—breast cancer	2.01e-05	9.32e-05	CcSEcCtD
Mesalazine—Constipation—Docetaxel—breast cancer	2.01e-05	9.32e-05	CcSEcCtD
Mesalazine—Pain—Docetaxel—breast cancer	2.01e-05	9.32e-05	CcSEcCtD
Mesalazine—Back pain—Methotrexate—breast cancer	2e-05	9.31e-05	CcSEcCtD
Mesalazine—Dyspepsia—Capecitabine—breast cancer	2e-05	9.29e-05	CcSEcCtD
Mesalazine—Chills—Epirubicin—breast cancer	2e-05	9.28e-05	CcSEcCtD
Mesalazine—Asthenia—Paclitaxel—breast cancer	1.99e-05	9.22e-05	CcSEcCtD
Mesalazine—Decreased appetite—Capecitabine—breast cancer	1.97e-05	9.17e-05	CcSEcCtD
Mesalazine—Alopecia—Epirubicin—breast cancer	1.97e-05	9.14e-05	CcSEcCtD
Mesalazine—Nausea—Gemcitabine—breast cancer	1.96e-05	9.12e-05	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Capecitabine—breast cancer	1.96e-05	9.11e-05	CcSEcCtD
Mesalazine—Fatigue—Capecitabine—breast cancer	1.96e-05	9.09e-05	CcSEcCtD
Mesalazine—Pruritus—Paclitaxel—breast cancer	1.96e-05	9.09e-05	CcSEcCtD
Mesalazine—Vision blurred—Methotrexate—breast cancer	1.95e-05	9.07e-05	CcSEcCtD
Mesalazine—Mental disorder—Epirubicin—breast cancer	1.95e-05	9.06e-05	CcSEcCtD
Mesalazine—Erythema multiforme—Doxorubicin—breast cancer	1.95e-05	9.05e-05	CcSEcCtD
Mesalazine—Constipation—Capecitabine—breast cancer	1.94e-05	9.02e-05	CcSEcCtD
Mesalazine—Pain—Capecitabine—breast cancer	1.94e-05	9.02e-05	CcSEcCtD
Mesalazine—Erythema—Epirubicin—breast cancer	1.94e-05	9e-05	CcSEcCtD
Mesalazine—Feeling abnormal—Docetaxel—breast cancer	1.93e-05	8.98e-05	CcSEcCtD
Mesalazine—Nausea—Fluorouracil—breast cancer	1.93e-05	8.97e-05	CcSEcCtD
Mesalazine—Eye disorder—Doxorubicin—breast cancer	1.93e-05	8.94e-05	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—breast cancer	1.92e-05	8.93e-05	CcSEcCtD
Mesalazine—Tinnitus—Doxorubicin—breast cancer	1.92e-05	8.92e-05	CcSEcCtD
Mesalazine—Gastrointestinal pain—Docetaxel—breast cancer	1.92e-05	8.91e-05	CcSEcCtD
Mesalazine—Anaemia—Methotrexate—breast cancer	1.92e-05	8.89e-05	CcSEcCtD
Mesalazine—Cardiac disorder—Doxorubicin—breast cancer	1.91e-05	8.88e-05	CcSEcCtD
Mesalazine—Flatulence—Epirubicin—breast cancer	1.91e-05	8.87e-05	CcSEcCtD
Mesalazine—Tension—Epirubicin—breast cancer	1.9e-05	8.84e-05	CcSEcCtD
Mesalazine—Dysgeusia—Epirubicin—breast cancer	1.9e-05	8.82e-05	CcSEcCtD
Mesalazine—Diarrhoea—Paclitaxel—breast cancer	1.89e-05	8.8e-05	CcSEcCtD
Mesalazine—Nervousness—Epirubicin—breast cancer	1.88e-05	8.75e-05	CcSEcCtD
Mesalazine—Back pain—Epirubicin—breast cancer	1.88e-05	8.71e-05	CcSEcCtD
Mesalazine—Feeling abnormal—Capecitabine—breast cancer	1.87e-05	8.69e-05	CcSEcCtD
Mesalazine—Angiopathy—Doxorubicin—breast cancer	1.87e-05	8.68e-05	CcSEcCtD
Mesalazine—Malaise—Methotrexate—breast cancer	1.87e-05	8.68e-05	CcSEcCtD
Mesalazine—Muscle spasms—Epirubicin—breast cancer	1.86e-05	8.66e-05	CcSEcCtD
Mesalazine—Immune system disorder—Doxorubicin—breast cancer	1.86e-05	8.65e-05	CcSEcCtD
Mesalazine—Vertigo—Methotrexate—breast cancer	1.86e-05	8.64e-05	CcSEcCtD
Mesalazine—Gastrointestinal pain—Capecitabine—breast cancer	1.86e-05	8.63e-05	CcSEcCtD
Mesalazine—Mediastinal disorder—Doxorubicin—breast cancer	1.86e-05	8.63e-05	CcSEcCtD
Mesalazine—Body temperature increased—Docetaxel—breast cancer	1.85e-05	8.61e-05	CcSEcCtD
Mesalazine—Abdominal pain—Docetaxel—breast cancer	1.85e-05	8.61e-05	CcSEcCtD
Mesalazine—Leukopenia—Methotrexate—breast cancer	1.85e-05	8.61e-05	CcSEcCtD
Mesalazine—Chills—Doxorubicin—breast cancer	1.85e-05	8.59e-05	CcSEcCtD
Mesalazine—Dizziness—Paclitaxel—breast cancer	1.83e-05	8.5e-05	CcSEcCtD
Mesalazine—Vision blurred—Epirubicin—breast cancer	1.83e-05	8.49e-05	CcSEcCtD
Mesalazine—Alopecia—Doxorubicin—breast cancer	1.82e-05	8.46e-05	CcSEcCtD
Mesalazine—Cough—Methotrexate—breast cancer	1.81e-05	8.4e-05	CcSEcCtD
Mesalazine—Mental disorder—Doxorubicin—breast cancer	1.81e-05	8.39e-05	CcSEcCtD
Mesalazine—Urticaria—Capecitabine—breast cancer	1.8e-05	8.38e-05	CcSEcCtD
Mesalazine—Ill-defined disorder—Epirubicin—breast cancer	1.8e-05	8.35e-05	CcSEcCtD
Mesalazine—Body temperature increased—Capecitabine—breast cancer	1.8e-05	8.34e-05	CcSEcCtD
Mesalazine—Abdominal pain—Capecitabine—breast cancer	1.8e-05	8.34e-05	CcSEcCtD
Mesalazine—Erythema—Doxorubicin—breast cancer	1.79e-05	8.33e-05	CcSEcCtD
Mesalazine—Anaemia—Epirubicin—breast cancer	1.79e-05	8.32e-05	CcSEcCtD
Mesalazine—Flatulence—Doxorubicin—breast cancer	1.77e-05	8.21e-05	CcSEcCtD
Mesalazine—Myalgia—Methotrexate—breast cancer	1.76e-05	8.19e-05	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—breast cancer	1.76e-05	8.19e-05	CcSEcCtD
Mesalazine—Arthralgia—Methotrexate—breast cancer	1.76e-05	8.19e-05	CcSEcCtD
Mesalazine—Tension—Doxorubicin—breast cancer	1.76e-05	8.18e-05	CcSEcCtD
Mesalazine—Vomiting—Paclitaxel—breast cancer	1.76e-05	8.17e-05	CcSEcCtD
Mesalazine—Dysgeusia—Doxorubicin—breast cancer	1.76e-05	8.16e-05	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.75e-05	8.14e-05	CcSEcCtD
Mesalazine—Malaise—Epirubicin—breast cancer	1.75e-05	8.12e-05	CcSEcCtD
Mesalazine—Rash—Paclitaxel—breast cancer	1.75e-05	8.11e-05	CcSEcCtD
Mesalazine—Dermatitis—Paclitaxel—breast cancer	1.74e-05	8.1e-05	CcSEcCtD
Mesalazine—Discomfort—Methotrexate—breast cancer	1.74e-05	8.09e-05	CcSEcCtD
Mesalazine—Nervousness—Doxorubicin—breast cancer	1.74e-05	8.09e-05	CcSEcCtD
Mesalazine—Vertigo—Epirubicin—breast cancer	1.74e-05	8.09e-05	CcSEcCtD
Mesalazine—Syncope—Epirubicin—breast cancer	1.74e-05	8.08e-05	CcSEcCtD
Mesalazine—Leukopenia—Epirubicin—breast cancer	1.74e-05	8.06e-05	CcSEcCtD
Mesalazine—Back pain—Doxorubicin—breast cancer	1.74e-05	8.06e-05	CcSEcCtD
Mesalazine—Headache—Paclitaxel—breast cancer	1.73e-05	8.05e-05	CcSEcCtD
Mesalazine—Hypersensitivity—Docetaxel—breast cancer	1.73e-05	8.03e-05	CcSEcCtD
Mesalazine—Muscle spasms—Doxorubicin—breast cancer	1.72e-05	8.01e-05	CcSEcCtD
Mesalazine—Palpitations—Epirubicin—breast cancer	1.71e-05	7.96e-05	CcSEcCtD
Mesalazine—Confusional state—Methotrexate—breast cancer	1.71e-05	7.92e-05	CcSEcCtD
Mesalazine—Loss of consciousness—Epirubicin—breast cancer	1.7e-05	7.91e-05	CcSEcCtD
Mesalazine—Cough—Epirubicin—breast cancer	1.69e-05	7.86e-05	CcSEcCtD
Mesalazine—Anaphylactic shock—Methotrexate—breast cancer	1.69e-05	7.85e-05	CcSEcCtD
Mesalazine—Vision blurred—Doxorubicin—breast cancer	1.69e-05	7.85e-05	CcSEcCtD
Mesalazine—Asthenia—Docetaxel—breast cancer	1.68e-05	7.82e-05	CcSEcCtD
Mesalazine—Infection—Methotrexate—breast cancer	1.68e-05	7.8e-05	CcSEcCtD
Mesalazine—Hypertension—Epirubicin—breast cancer	1.67e-05	7.77e-05	CcSEcCtD
Mesalazine—Hypersensitivity—Capecitabine—breast cancer	1.67e-05	7.77e-05	CcSEcCtD
Mesalazine—Ill-defined disorder—Doxorubicin—breast cancer	1.66e-05	7.73e-05	CcSEcCtD
Mesalazine—Pruritus—Docetaxel—breast cancer	1.66e-05	7.71e-05	CcSEcCtD
Mesalazine—Nervous system disorder—Methotrexate—breast cancer	1.66e-05	7.7e-05	CcSEcCtD
Mesalazine—Anaemia—Doxorubicin—breast cancer	1.66e-05	7.7e-05	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—breast cancer	1.66e-05	7.69e-05	CcSEcCtD
Mesalazine—Chest pain—Epirubicin—breast cancer	1.65e-05	7.67e-05	CcSEcCtD
Mesalazine—Myalgia—Epirubicin—breast cancer	1.65e-05	7.67e-05	CcSEcCtD
Mesalazine—Arthralgia—Epirubicin—breast cancer	1.65e-05	7.67e-05	CcSEcCtD
Mesalazine—Anxiety—Epirubicin—breast cancer	1.65e-05	7.64e-05	CcSEcCtD
Mesalazine—Nausea—Paclitaxel—breast cancer	1.64e-05	7.64e-05	CcSEcCtD
Mesalazine—Skin disorder—Methotrexate—breast cancer	1.64e-05	7.63e-05	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.64e-05	7.61e-05	CcSEcCtD
Mesalazine—Hyperhidrosis—Methotrexate—breast cancer	1.63e-05	7.59e-05	CcSEcCtD
Mesalazine—Discomfort—Epirubicin—breast cancer	1.63e-05	7.57e-05	CcSEcCtD
Mesalazine—Asthenia—Capecitabine—breast cancer	1.63e-05	7.57e-05	CcSEcCtD
Mesalazine—Malaise—Doxorubicin—breast cancer	1.62e-05	7.51e-05	CcSEcCtD
Mesalazine—Dry mouth—Epirubicin—breast cancer	1.61e-05	7.5e-05	CcSEcCtD
Mesalazine—Vertigo—Doxorubicin—breast cancer	1.61e-05	7.49e-05	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—breast cancer	1.61e-05	7.49e-05	CcSEcCtD
Mesalazine—Syncope—Doxorubicin—breast cancer	1.61e-05	7.47e-05	CcSEcCtD
Mesalazine—Pruritus—Capecitabine—breast cancer	1.61e-05	7.46e-05	CcSEcCtD
Mesalazine—Leukopenia—Doxorubicin—breast cancer	1.61e-05	7.46e-05	CcSEcCtD
Mesalazine—Diarrhoea—Docetaxel—breast cancer	1.61e-05	7.45e-05	CcSEcCtD
Mesalazine—Confusional state—Epirubicin—breast cancer	1.6e-05	7.41e-05	CcSEcCtD
Mesalazine—Palpitations—Doxorubicin—breast cancer	1.59e-05	7.36e-05	CcSEcCtD
Mesalazine—Oedema—Epirubicin—breast cancer	1.58e-05	7.35e-05	CcSEcCtD
Mesalazine—Anaphylactic shock—Epirubicin—breast cancer	1.58e-05	7.35e-05	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—breast cancer	1.58e-05	7.34e-05	CcSEcCtD
Mesalazine—Loss of consciousness—Doxorubicin—breast cancer	1.58e-05	7.32e-05	CcSEcCtD
Mesalazine—Infection—Epirubicin—breast cancer	1.57e-05	7.3e-05	CcSEcCtD
Mesalazine—Cough—Doxorubicin—breast cancer	1.57e-05	7.27e-05	CcSEcCtD
Mesalazine—Shock—Epirubicin—breast cancer	1.56e-05	7.23e-05	CcSEcCtD
Mesalazine—Diarrhoea—Capecitabine—breast cancer	1.55e-05	7.22e-05	CcSEcCtD
Mesalazine—Nervous system disorder—Epirubicin—breast cancer	1.55e-05	7.21e-05	CcSEcCtD
Mesalazine—Dizziness—Docetaxel—breast cancer	1.55e-05	7.21e-05	CcSEcCtD
Mesalazine—Thrombocytopenia—Epirubicin—breast cancer	1.55e-05	7.2e-05	CcSEcCtD
Mesalazine—Hypertension—Doxorubicin—breast cancer	1.55e-05	7.19e-05	CcSEcCtD
Mesalazine—Tachycardia—Epirubicin—breast cancer	1.54e-05	7.17e-05	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Methotrexate—breast cancer	1.54e-05	7.15e-05	CcSEcCtD
Mesalazine—Skin disorder—Epirubicin—breast cancer	1.54e-05	7.14e-05	CcSEcCtD
Mesalazine—Hyperhidrosis—Epirubicin—breast cancer	1.53e-05	7.1e-05	CcSEcCtD
Mesalazine—Insomnia—Methotrexate—breast cancer	1.53e-05	7.1e-05	CcSEcCtD
Mesalazine—Arthralgia—Doxorubicin—breast cancer	1.53e-05	7.09e-05	CcSEcCtD
Mesalazine—Myalgia—Doxorubicin—breast cancer	1.53e-05	7.09e-05	CcSEcCtD
Mesalazine—Chest pain—Doxorubicin—breast cancer	1.53e-05	7.09e-05	CcSEcCtD
Mesalazine—Anxiety—Doxorubicin—breast cancer	1.52e-05	7.07e-05	CcSEcCtD
Mesalazine—Paraesthesia—Methotrexate—breast cancer	1.52e-05	7.05e-05	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.52e-05	7.04e-05	CcSEcCtD
Mesalazine—Discomfort—Doxorubicin—breast cancer	1.51e-05	7.01e-05	CcSEcCtD
Mesalazine—Anorexia—Epirubicin—breast cancer	1.51e-05	7.01e-05	CcSEcCtD
Mesalazine—Dyspnoea—Methotrexate—breast cancer	1.51e-05	7e-05	CcSEcCtD
Mesalazine—Somnolence—Methotrexate—breast cancer	1.5e-05	6.98e-05	CcSEcCtD
Mesalazine—Dizziness—Capecitabine—breast cancer	1.5e-05	6.98e-05	CcSEcCtD
Mesalazine—Dry mouth—Doxorubicin—breast cancer	1.49e-05	6.94e-05	CcSEcCtD
Mesalazine—Vomiting—Docetaxel—breast cancer	1.49e-05	6.93e-05	CcSEcCtD
Mesalazine—Dyspepsia—Methotrexate—breast cancer	1.49e-05	6.91e-05	CcSEcCtD
Mesalazine—Rash—Docetaxel—breast cancer	1.48e-05	6.87e-05	CcSEcCtD
Mesalazine—Hypotension—Epirubicin—breast cancer	1.48e-05	6.87e-05	CcSEcCtD
Mesalazine—Dermatitis—Docetaxel—breast cancer	1.48e-05	6.86e-05	CcSEcCtD
Mesalazine—Confusional state—Doxorubicin—breast cancer	1.48e-05	6.86e-05	CcSEcCtD
Mesalazine—Decreased appetite—Methotrexate—breast cancer	1.47e-05	6.83e-05	CcSEcCtD
Mesalazine—Headache—Docetaxel—breast cancer	1.47e-05	6.83e-05	CcSEcCtD
Mesalazine—Oedema—Doxorubicin—breast cancer	1.46e-05	6.8e-05	CcSEcCtD
Mesalazine—Anaphylactic shock—Doxorubicin—breast cancer	1.46e-05	6.8e-05	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Methotrexate—breast cancer	1.46e-05	6.78e-05	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—breast cancer	1.46e-05	6.77e-05	CcSEcCtD
Mesalazine—Infection—Doxorubicin—breast cancer	1.45e-05	6.76e-05	CcSEcCtD
Mesalazine—Pain—Methotrexate—breast cancer	1.45e-05	6.72e-05	CcSEcCtD
Mesalazine—Vomiting—Capecitabine—breast cancer	1.44e-05	6.71e-05	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Epirubicin—breast cancer	1.44e-05	6.7e-05	CcSEcCtD
Mesalazine—Shock—Doxorubicin—breast cancer	1.44e-05	6.69e-05	CcSEcCtD
Mesalazine—Nervous system disorder—Doxorubicin—breast cancer	1.44e-05	6.67e-05	CcSEcCtD
Mesalazine—Thrombocytopenia—Doxorubicin—breast cancer	1.43e-05	6.66e-05	CcSEcCtD
Mesalazine—Rash—Capecitabine—breast cancer	1.43e-05	6.65e-05	CcSEcCtD
Mesalazine—Insomnia—Epirubicin—breast cancer	1.43e-05	6.65e-05	CcSEcCtD
Mesalazine—Dermatitis—Capecitabine—breast cancer	1.43e-05	6.65e-05	CcSEcCtD
Mesalazine—Tachycardia—Doxorubicin—breast cancer	1.43e-05	6.64e-05	CcSEcCtD
Mesalazine—Headache—Capecitabine—breast cancer	1.42e-05	6.61e-05	CcSEcCtD
Mesalazine—Skin disorder—Doxorubicin—breast cancer	1.42e-05	6.6e-05	CcSEcCtD
Mesalazine—Paraesthesia—Epirubicin—breast cancer	1.42e-05	6.6e-05	CcSEcCtD
Mesalazine—Hyperhidrosis—Doxorubicin—breast cancer	1.42e-05	6.57e-05	CcSEcCtD
Mesalazine—Dyspnoea—Epirubicin—breast cancer	1.41e-05	6.55e-05	CcSEcCtD
Mesalazine—Somnolence—Epirubicin—breast cancer	1.41e-05	6.53e-05	CcSEcCtD
Mesalazine—Anorexia—Doxorubicin—breast cancer	1.4e-05	6.48e-05	CcSEcCtD
Mesalazine—Nausea—Docetaxel—breast cancer	1.39e-05	6.47e-05	CcSEcCtD
Mesalazine—Feeling abnormal—Methotrexate—breast cancer	1.39e-05	6.47e-05	CcSEcCtD
Mesalazine—Dyspepsia—Epirubicin—breast cancer	1.39e-05	6.47e-05	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methotrexate—breast cancer	1.38e-05	6.42e-05	CcSEcCtD
Mesalazine—Decreased appetite—Epirubicin—breast cancer	1.38e-05	6.39e-05	CcSEcCtD
Mesalazine—Hypotension—Doxorubicin—breast cancer	1.37e-05	6.35e-05	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Epirubicin—breast cancer	1.37e-05	6.34e-05	CcSEcCtD
Mesalazine—Fatigue—Epirubicin—breast cancer	1.36e-05	6.34e-05	CcSEcCtD
Mesalazine—Constipation—Epirubicin—breast cancer	1.35e-05	6.28e-05	CcSEcCtD
Mesalazine—Pain—Epirubicin—breast cancer	1.35e-05	6.28e-05	CcSEcCtD
Mesalazine—Nausea—Capecitabine—breast cancer	1.35e-05	6.27e-05	CcSEcCtD
Mesalazine—Urticaria—Methotrexate—breast cancer	1.34e-05	6.24e-05	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—breast cancer	1.34e-05	6.21e-05	CcSEcCtD
Mesalazine—Body temperature increased—Methotrexate—breast cancer	1.34e-05	6.21e-05	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.33e-05	6.2e-05	CcSEcCtD
Mesalazine—Insomnia—Doxorubicin—breast cancer	1.32e-05	6.15e-05	CcSEcCtD
Mesalazine—Paraesthesia—Doxorubicin—breast cancer	1.31e-05	6.11e-05	CcSEcCtD
Mesalazine—Dyspnoea—Doxorubicin—breast cancer	1.31e-05	6.06e-05	CcSEcCtD
Mesalazine—Feeling abnormal—Epirubicin—breast cancer	1.3e-05	6.06e-05	CcSEcCtD
Mesalazine—Somnolence—Doxorubicin—breast cancer	1.3e-05	6.05e-05	CcSEcCtD
Mesalazine—Gastrointestinal pain—Epirubicin—breast cancer	1.29e-05	6.01e-05	CcSEcCtD
Mesalazine—Dyspepsia—Doxorubicin—breast cancer	1.29e-05	5.99e-05	CcSEcCtD
Mesalazine—Decreased appetite—Doxorubicin—breast cancer	1.27e-05	5.91e-05	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Doxorubicin—breast cancer	1.26e-05	5.87e-05	CcSEcCtD
Mesalazine—Fatigue—Doxorubicin—breast cancer	1.26e-05	5.86e-05	CcSEcCtD
Mesalazine—Urticaria—Epirubicin—breast cancer	1.26e-05	5.84e-05	CcSEcCtD
Mesalazine—Constipation—Doxorubicin—breast cancer	1.25e-05	5.81e-05	CcSEcCtD
Mesalazine—Pain—Doxorubicin—breast cancer	1.25e-05	5.81e-05	CcSEcCtD
Mesalazine—Abdominal pain—Epirubicin—breast cancer	1.25e-05	5.81e-05	CcSEcCtD
Mesalazine—Body temperature increased—Epirubicin—breast cancer	1.25e-05	5.81e-05	CcSEcCtD
Mesalazine—Hypersensitivity—Methotrexate—breast cancer	1.25e-05	5.79e-05	CcSEcCtD
Mesalazine—Asthenia—Methotrexate—breast cancer	1.21e-05	5.63e-05	CcSEcCtD
Mesalazine—Feeling abnormal—Doxorubicin—breast cancer	1.21e-05	5.6e-05	CcSEcCtD
Mesalazine—Gastrointestinal pain—Doxorubicin—breast cancer	1.2e-05	5.56e-05	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—breast cancer	1.2e-05	5.56e-05	CcSEcCtD
Mesalazine—Hypersensitivity—Epirubicin—breast cancer	1.17e-05	5.41e-05	CcSEcCtD
Mesalazine—Urticaria—Doxorubicin—breast cancer	1.16e-05	5.4e-05	CcSEcCtD
Mesalazine—Abdominal pain—Doxorubicin—breast cancer	1.16e-05	5.38e-05	CcSEcCtD
Mesalazine—Body temperature increased—Doxorubicin—breast cancer	1.16e-05	5.38e-05	CcSEcCtD
Mesalazine—Diarrhoea—Methotrexate—breast cancer	1.16e-05	5.37e-05	CcSEcCtD
Mesalazine—Asthenia—Epirubicin—breast cancer	1.14e-05	5.27e-05	CcSEcCtD
Mesalazine—Pruritus—Epirubicin—breast cancer	1.12e-05	5.2e-05	CcSEcCtD
Mesalazine—Dizziness—Methotrexate—breast cancer	1.12e-05	5.19e-05	CcSEcCtD
Mesalazine—Diarrhoea—Epirubicin—breast cancer	1.08e-05	5.03e-05	CcSEcCtD
Mesalazine—Hypersensitivity—Doxorubicin—breast cancer	1.08e-05	5.01e-05	CcSEcCtD
Mesalazine—Vomiting—Methotrexate—breast cancer	1.08e-05	4.99e-05	CcSEcCtD
Mesalazine—Rash—Methotrexate—breast cancer	1.07e-05	4.95e-05	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—breast cancer	1.07e-05	4.95e-05	CcSEcCtD
Mesalazine—Headache—Methotrexate—breast cancer	1.06e-05	4.92e-05	CcSEcCtD
Mesalazine—Asthenia—Doxorubicin—breast cancer	1.05e-05	4.88e-05	CcSEcCtD
Mesalazine—Dizziness—Epirubicin—breast cancer	1.05e-05	4.86e-05	CcSEcCtD
Mesalazine—Pruritus—Doxorubicin—breast cancer	1.04e-05	4.81e-05	CcSEcCtD
Mesalazine—Vomiting—Epirubicin—breast cancer	1.01e-05	4.67e-05	CcSEcCtD
Mesalazine—Nausea—Methotrexate—breast cancer	1e-05	4.66e-05	CcSEcCtD
Mesalazine—Diarrhoea—Doxorubicin—breast cancer	1e-05	4.65e-05	CcSEcCtD
Mesalazine—Rash—Epirubicin—breast cancer	9.98e-06	4.63e-05	CcSEcCtD
Mesalazine—Dermatitis—Epirubicin—breast cancer	9.97e-06	4.63e-05	CcSEcCtD
Mesalazine—Headache—Epirubicin—breast cancer	9.91e-06	4.6e-05	CcSEcCtD
Mesalazine—Dizziness—Doxorubicin—breast cancer	9.68e-06	4.5e-05	CcSEcCtD
Mesalazine—Nausea—Epirubicin—breast cancer	9.4e-06	4.37e-05	CcSEcCtD
Mesalazine—Vomiting—Doxorubicin—breast cancer	9.31e-06	4.32e-05	CcSEcCtD
Mesalazine—Rash—Doxorubicin—breast cancer	9.23e-06	4.29e-05	CcSEcCtD
Mesalazine—Dermatitis—Doxorubicin—breast cancer	9.22e-06	4.28e-05	CcSEcCtD
Mesalazine—Headache—Doxorubicin—breast cancer	9.17e-06	4.26e-05	CcSEcCtD
Mesalazine—Nausea—Doxorubicin—breast cancer	8.7e-06	4.04e-05	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—HRAS—breast cancer	3.14e-06	1.92e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—RAF1—breast cancer	3.13e-06	1.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6—breast cancer	3.13e-06	1.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CAV1—breast cancer	3.13e-06	1.91e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—RELA—breast cancer	3.12e-06	1.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MTOR—breast cancer	3.11e-06	1.9e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CB—breast cancer	3.11e-06	1.9e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL1B—breast cancer	3.11e-06	1.9e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CD4—breast cancer	3.11e-06	1.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ERBB2—breast cancer	3.1e-06	1.89e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL2—breast cancer	3.1e-06	1.89e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KDR—breast cancer	3.09e-06	1.89e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—breast cancer	3.09e-06	1.89e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PIK3CA—breast cancer	3.07e-06	1.88e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TERT—breast cancer	3.06e-06	1.87e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CB—breast cancer	3.06e-06	1.87e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MTOR—breast cancer	3.06e-06	1.87e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD4—breast cancer	3.05e-06	1.87e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERCC2—breast cancer	3.05e-06	1.86e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—MTHFR—breast cancer	3.02e-06	1.85e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—JUN—breast cancer	3.01e-06	1.84e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ESR1—breast cancer	3.01e-06	1.84e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—NOS3—breast cancer	3.01e-06	1.84e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	3e-06	1.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CTNNB1—breast cancer	2.99e-06	1.83e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB3—breast cancer	2.98e-06	1.82e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGFR2—breast cancer	2.98e-06	1.82e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGFR1—breast cancer	2.97e-06	1.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FN1—breast cancer	2.97e-06	1.82e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—COMT—breast cancer	2.97e-06	1.81e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—breast cancer	2.96e-06	1.81e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTP1—breast cancer	2.96e-06	1.81e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NFKBIA—breast cancer	2.94e-06	1.8e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HIF1A—breast cancer	2.93e-06	1.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1B—breast cancer	2.92e-06	1.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDKN1A—breast cancer	2.92e-06	1.78e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTEN—breast cancer	2.92e-06	1.78e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—HMOX1—breast cancer	2.91e-06	1.78e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOTCH1—breast cancer	2.91e-06	1.78e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ITPR1—breast cancer	2.91e-06	1.78e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—breast cancer	2.88e-06	1.76e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1B—breast cancer	2.87e-06	1.75e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTHFR—breast cancer	2.87e-06	1.75e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—LEP—breast cancer	2.86e-06	1.75e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TERT—breast cancer	2.86e-06	1.75e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK8—breast cancer	2.85e-06	1.74e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CG—breast cancer	2.85e-06	1.74e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KIT—breast cancer	2.85e-06	1.74e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APC—breast cancer	2.85e-06	1.74e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—breast cancer	2.84e-06	1.74e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6—breast cancer	2.84e-06	1.73e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CAV1—breast cancer	2.83e-06	1.73e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL1B—breast cancer	2.82e-06	1.72e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGF—breast cancer	2.81e-06	1.72e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL2—breast cancer	2.81e-06	1.72e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KDR—breast cancer	2.8e-06	1.71e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ABCB1—breast cancer	2.8e-06	1.71e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CAV1—breast cancer	2.79e-06	1.7e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CB—breast cancer	2.78e-06	1.7e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGFR1—breast cancer	2.78e-06	1.7e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—breast cancer	2.77e-06	1.69e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CTNNB1—breast cancer	2.76e-06	1.69e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—breast cancer	2.75e-06	1.68e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TYMS—breast cancer	2.75e-06	1.68e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CA—breast cancer	2.74e-06	1.67e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HIF1A—breast cancer	2.73e-06	1.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—JUN—breast cancer	2.73e-06	1.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ESR1—breast cancer	2.73e-06	1.67e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PLA2G4A—breast cancer	2.72e-06	1.66e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NCOR1—breast cancer	2.72e-06	1.66e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTM1—breast cancer	2.72e-06	1.66e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CTNNB1—breast cancer	2.71e-06	1.66e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—SRC—breast cancer	2.7e-06	1.65e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1A—breast cancer	2.7e-06	1.65e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FN1—breast cancer	2.7e-06	1.65e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTEN—breast cancer	2.69e-06	1.64e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—BRAF—breast cancer	2.68e-06	1.63e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NFKBIA—breast cancer	2.67e-06	1.63e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.66e-06	1.63e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1A—breast cancer	2.65e-06	1.62e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CAV1—breast cancer	2.64e-06	1.61e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTEN—breast cancer	2.64e-06	1.61e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOTCH1—breast cancer	2.64e-06	1.61e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MAPK3—breast cancer	2.64e-06	1.61e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—breast cancer	2.62e-06	1.6e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—STAT3—breast cancer	2.61e-06	1.59e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF1—breast cancer	2.61e-06	1.59e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT2—breast cancer	2.6e-06	1.59e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GPX1—breast cancer	2.6e-06	1.59e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK8—breast cancer	2.59e-06	1.58e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APC—breast cancer	2.58e-06	1.58e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CG—breast cancer	2.58e-06	1.58e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KIT—breast cancer	2.58e-06	1.58e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP1A1—breast cancer	2.57e-06	1.57e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—breast cancer	2.57e-06	1.57e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ERCC2—breast cancer	2.55e-06	1.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGF—breast cancer	2.55e-06	1.56e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CG—breast cancer	2.54e-06	1.55e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—breast cancer	2.51e-06	1.53e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CD—breast cancer	2.5e-06	1.53e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—SRC—breast cancer	2.5e-06	1.52e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK3—breast cancer	2.49e-06	1.52e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS2—breast cancer	2.49e-06	1.52e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SERPINE1—breast cancer	2.48e-06	1.51e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOTCH1—breast cancer	2.46e-06	1.5e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—SRC—breast cancer	2.45e-06	1.5e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—BRAF—breast cancer	2.43e-06	1.48e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KIT—breast cancer	2.41e-06	1.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APC—breast cancer	2.41e-06	1.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—STAT3—breast cancer	2.41e-06	1.47e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTEN—breast cancer	2.4e-06	1.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—MTHFR—breast cancer	2.4e-06	1.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGF—breast cancer	2.38e-06	1.45e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—breast cancer	2.37e-06	1.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—STAT3—breast cancer	2.36e-06	1.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF1—breast cancer	2.36e-06	1.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOS3—breast cancer	2.36e-06	1.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT2—breast cancer	2.36e-06	1.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK3—breast cancer	2.3e-06	1.4e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CD—breast cancer	2.27e-06	1.39e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—BRAF—breast cancer	2.26e-06	1.38e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK3—breast cancer	2.26e-06	1.38e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SERPINE1—breast cancer	2.24e-06	1.37e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MDM2—breast cancer	2.24e-06	1.37e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—breast cancer	2.24e-06	1.37e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—breast cancer	2.24e-06	1.37e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—breast cancer	2.24e-06	1.37e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RAF1—breast cancer	2.23e-06	1.36e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CD—breast cancer	2.23e-06	1.36e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—TGFB1—breast cancer	2.23e-06	1.36e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RELA—breast cancer	2.22e-06	1.36e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CAV1—breast cancer	2.21e-06	1.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ERBB2—breast cancer	2.21e-06	1.35e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ALB—breast cancer	2.2e-06	1.35e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT2—breast cancer	2.2e-06	1.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—breast cancer	2.19e-06	1.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CB—breast cancer	2.18e-06	1.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MTOR—breast cancer	2.18e-06	1.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—breast cancer	2.15e-06	1.31e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOS3—breast cancer	2.14e-06	1.31e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CD—breast cancer	2.12e-06	1.29e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.12e-06	1.29e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NOS3—breast cancer	2.11e-06	1.29e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL8—breast cancer	2.1e-06	1.28e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SERPINE1—breast cancer	2.09e-06	1.28e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—breast cancer	2.07e-06	1.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CA—breast cancer	2.06e-06	1.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1B—breast cancer	2.05e-06	1.25e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MDM2—breast cancer	2.03e-06	1.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—breast cancer	2.03e-06	1.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RAF1—breast cancer	2.03e-06	1.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RELA—breast cancer	2.02e-06	1.23e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CG—breast cancer	2.02e-06	1.23e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CASP3—breast cancer	2.01e-06	1.23e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ERBB2—breast cancer	2e-06	1.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL2—breast cancer	2e-06	1.22e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS3—breast cancer	2e-06	1.22e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MTOR—breast cancer	1.98e-06	1.21e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CB—breast cancer	1.98e-06	1.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCND1—breast cancer	1.95e-06	1.19e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—JUN—breast cancer	1.95e-06	1.19e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CB—breast cancer	1.95e-06	1.19e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CTNNB1—breast cancer	1.93e-06	1.18e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—breast cancer	1.93e-06	1.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—breast cancer	1.9e-06	1.16e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL8—breast cancer	1.9e-06	1.16e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CA—breast cancer	1.9e-06	1.16e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MDM2—breast cancer	1.9e-06	1.16e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—breast cancer	1.9e-06	1.16e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RAF1—breast cancer	1.89e-06	1.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1A—breast cancer	1.89e-06	1.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTEN—breast cancer	1.88e-06	1.15e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB2—breast cancer	1.87e-06	1.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CA—breast cancer	1.86e-06	1.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1B—breast cancer	1.86e-06	1.13e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTOR—breast cancer	1.85e-06	1.13e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CB—breast cancer	1.85e-06	1.13e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK8—breast cancer	1.84e-06	1.13e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD4—breast cancer	1.84e-06	1.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6—breast cancer	1.82e-06	1.11e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CASP3—breast cancer	1.82e-06	1.11e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL2—breast cancer	1.82e-06	1.11e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—breast cancer	1.78e-06	1.09e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CD—breast cancer	1.77e-06	1.08e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCND1—breast cancer	1.77e-06	1.08e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—JUN—breast cancer	1.77e-06	1.08e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—breast cancer	1.76e-06	1.07e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CTNNB1—breast cancer	1.75e-06	1.07e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ALB—breast cancer	1.75e-06	1.07e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SRC—breast cancer	1.75e-06	1.07e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1B—breast cancer	1.73e-06	1.06e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—breast cancer	1.73e-06	1.05e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—breast cancer	1.72e-06	1.05e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1A—breast cancer	1.71e-06	1.05e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTEN—breast cancer	1.71e-06	1.04e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—breast cancer	1.7e-06	1.04e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CA—breast cancer	1.69e-06	1.03e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STAT3—breast cancer	1.69e-06	1.03e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTEN—breast cancer	1.68e-06	1.03e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6—breast cancer	1.68e-06	1.03e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—breast cancer	1.68e-06	1.03e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NOS3—breast cancer	1.67e-06	1.02e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK8—breast cancer	1.67e-06	1.02e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6—breast cancer	1.65e-06	1.01e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CTNNB1—breast cancer	1.64e-06	9.99e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK3—breast cancer	1.61e-06	9.84e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1A—breast cancer	1.6e-06	9.76e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTEN—breast cancer	1.59e-06	9.74e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SRC—breast cancer	1.58e-06	9.68e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—breast cancer	1.57e-06	9.57e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TGFB1—breast cancer	1.56e-06	9.54e-06	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—breast cancer	1.55e-06	9.47e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CB—breast cancer	1.55e-06	9.44e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—breast cancer	1.54e-06	9.43e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—breast cancer	1.53e-06	9.36e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STAT3—breast cancer	1.53e-06	9.34e-06	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—breast cancer	1.52e-06	9.31e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SRC—breast cancer	1.48e-06	9.03e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK3—breast cancer	1.46e-06	8.92e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—breast cancer	1.45e-06	8.84e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—STAT3—breast cancer	1.43e-06	8.71e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—breast cancer	1.42e-06	8.68e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TGFB1—breast cancer	1.42e-06	8.65e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—breast cancer	1.39e-06	8.49e-06	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—breast cancer	1.38e-06	8.45e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK3—breast cancer	1.36e-06	8.32e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTEN—breast cancer	1.34e-06	8.16e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CA—breast cancer	1.33e-06	8.12e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—breast cancer	1.32e-06	8.09e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TGFB1—breast cancer	1.32e-06	8.07e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—breast cancer	1.31e-06	8.02e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—breast cancer	1.3e-06	7.92e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—breast cancer	1.29e-06	7.86e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—breast cancer	1.23e-06	7.51e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—breast cancer	1.22e-06	7.48e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CA—breast cancer	1.21e-06	7.36e-06	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CA—breast cancer	1.19e-06	7.25e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6—breast cancer	1.18e-06	7.19e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—breast cancer	1.17e-06	7.12e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CA—breast cancer	1.12e-06	6.87e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—breast cancer	1.12e-06	6.81e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—breast cancer	1.09e-06	6.63e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6—breast cancer	1.07e-06	6.52e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—breast cancer	1.04e-06	6.36e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6—breast cancer	9.96e-07	6.08e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—breast cancer	9.85e-07	6.02e-06	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—breast cancer	9.69e-07	5.92e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CA—breast cancer	9.42e-07	5.75e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—breast cancer	9.19e-07	5.61e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—breast cancer	7.69e-07	4.7e-06	CbGpPWpGaD
